Compare HLLY & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | ZNTL |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.6M | 289.0M |
| IPO Year | 2020 | 2020 |
| Metric | HLLY | ZNTL |
|---|---|---|
| Price | $2.13 | $1.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $4.58 | ★ $7.33 |
| AVG Volume (30 Days) | 901.9K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 180.00 | 18.03 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $613,514,000.00 | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $29.00 | ★ N/A |
| Revenue Growth | ★ 1.87 | N/A |
| 52 Week Low | $2.25 | $1.25 |
| 52 Week High | $4.48 | $6.95 |
| Indicator | HLLY | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 29.38 |
| Support Level | N/A | N/A |
| Resistance Level | $2.66 | $2.76 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.99 | 17.26 |
Holley Inc designs, manufactures, and distributes high-performance automotive aftermarket products to car and truck enthusiasts in the United States, Canada and Europe. It manufactures a diversified line of performance automotive products, including carburetors, fuel pumps, fuel injection systems, nitrous oxide injection systems, superchargers, exhaust headers, mufflers, distributors, ignition components, engine tuners and automotive performance plumbing products. It also manufactures exhaust products as well as shifters, converters, transmission kits, transmissions, tuners and automotive software. The company markets its products under brands such as Holley, Holley EFI, MSD, Simpson, Flowmaster, EDGE, Cataclean, and Accel, among others. It operates in single segment.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.